Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib safety confirmation in pediatric relapsed or refractory Philadelphia chromosome-positive leukemia
jRCTs041190048Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ponatinib in Philadelphia-chromosome positive acute lymphoblastic leukemia, chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Fixed dose toxicity. Started Nov 2019; status: completed.
02
Drugs
ponatinib
03
Conditions
Philadelphia-chromosome positive acute lymphoblastic leukemiachronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCTs041190048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190048.